ResoluteAI unveils new tools to streamline post market surveillance and pharmacovigilance research
NEW YORK, April 8, 2021 /PRNewswire/ -- ResoluteAI, the research platform for science, today released a set of tools to streamline post market surveillance and pharmacovigilance analysis. Using data available from OpenFDA, ResoluteAI has connected and enhanced access to six FDA databases:
These databases can now be searched simultaneously, creating a simplified and more efficient research, reporting, and analytical search experience. Users can view records together to better understand important and relevant connections that may have been hard to see otherwise.
ResoluteAI users can apply additional research and analytic tools to the FDA databases during their discvery process. They can:
"The FDA provides an invaluable service by making its numerous standalone datasets readily accessible. We've connected these datasets with each other along with other datasets that professionals use for post market surveillance and pharmacovigilance," said Steve Goldstein, CEO of ResoluteAI. "By connecting datasets with news, academic publications, patents, and clinical trials, our customers can conduct more comprehensive research on drugs and medical devices."
View original content to download multimedia:http://www.prnewswire.com/news-releases/resoluteai-unveils-new-tools-to-streamline-post-market-surveillance-and-pharmacovigilance-research-301265053.html
The New Era of Wireless Access and the Great Disconnect